TRANSDERMAL THERAPEUTIC SYSTEM
First Claim
Patent Images
1. A Transdermal Therapeutic System (TTS) comprising a) a backing layer, b) a reservoir layer comprising one or more pharmaceutically active ingredients and one or more polymers, c) an adhesive layer comprising a silicone polymer and a tackifier.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use.
90 Citations
28 Claims
-
1. A Transdermal Therapeutic System (TTS) comprising
a) a backing layer, b) a reservoir layer comprising one or more pharmaceutically active ingredients and one or more polymers, c) an adhesive layer comprising a silicone polymer and a tackifier.
-
4. A TTS comprising
a) a backing layer, b) a reservoir layer containing at least one pharmaceutically active ingredient in the form of a polymer matrix and c) an adhesive layer that has an adhesive force between 10 N/TTS and 100 N/TTS.
-
17. A TTS comprising as active ingredient rivastigmine in free base or pharmaceutically acceptable salt form and providing a maximum plasma concentration of about 1 to 30 ng/ml from a mean of about 2 to 16 hours after application.
-
18. A TTS comprising as active ingredient rivastigmine in free base or pharmaceutically acceptable salt form and providing a maximum plasma concentration of about 2.5 to 20 ng/ml from a mean of about 4 to 12 hours after application.
-
19. A TTS comprising as active ingredient rivastigmine in free base or pharmaceutically acceptable salt form and having an AUC24h of about 25 to 450 ng*h/mL after repeated once daily administration.
-
20. A TTS comprising as active ingredient rivastigmine in free base or pharmaceutically acceptable salt form and an having an AUC24h of about 45 to 340 ng*h/mL after repeated once daily administration.
Specification